Local view for "http://wifo5-04.informatik.uni-mannheim.de/drugbank/resource/drugs/DB01341"
| Predicate | Value (sorted: none) |
|---|---|
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| rdf:type | |
| owl:sameAs | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| rdfs:label |
"Dihydroquinidine barbiturate"
|
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:description |
"
experimental
Barbiturates work by binding to the GABAA receptor at either the alpha or the beta sub unit. These are binding sites that are distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA at this receptor. This GABAA receptor binding decreases input resistance, depresses burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increases both the amplitude and decay time of inhibitory postsynaptic currents. In addition to this GABA-ergic effect, barbiturates also block the AMPA receptor, a subtype of glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the mammalian CNS.
DB00594
Amiloride
Decreases the antiarrhythmic effect of quinidine
DB01223
Aminophylline
The barbiturate, dihydroquinidine barbiturate, decreases the effect of aminophylline.
DB01118
Amiodarone
Increases the effect of quinidine
DB00321
Amitriptyline
Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, amitriptyline.
DB01238
Aripiprazole
Quinidine increases the effect and toxicity of aripiprazole
DB01072
Atazanavir
Increased risk of cardiotoxicity and arrhythmias
DB00443
Betamethasone
The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone.
DB00501
Cimetidine
Increases the effect of quinidine
DB00604
Cisapride
Increased risk of cardiotoxicity and arrhythmias
DB01242
Clomipramine
Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, clomipramine.
DB00318
Codeine
Quinidine decreases the analgesic effect of codeine
DB00091
Cyclosporine
The barbiturate, dihydroquinidine barbiturate, increases the effect of cyclosporine.
DB01151
Desipramine
Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, desipramine.
DB01234
Dexamethasone
The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone.
DB00514
Dextromethorphan
Quinidine increases the toxicity of dextromethorphan
DB00390
Digoxin
Quinine/quinidine increases the effect of digoxin
DB00343
Diltiazem
Increases the effect and toxicity of quinidine
DB01142
Doxepin
Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, doxepin.
DB00254
Doxycycline
The anticonvulsant, dihydroquinidine barbiturate, decreases the effect of doxycycline.
DB01023
Felodipine
The barbiturate, dihydroquinidine barbiturate, decreases the effect of felodipine.
DB00687
Fludrocortisone
The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone.
DB00158
Folic Acid
Folic acid decreases the effect of anticonvulsant, dihydroquinidine barbiturate.
DB01044
Gatifloxacin
Increased risk of cardiotoxicity and arrhythmias
DB00317
Gefitinib
The CYP3A4 inducer, dihydroquinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00365
Grepafloxacin
Increased risk of cardiotoxicity and arrhythmias
DB00400
Griseofulvin
The barbiturate, dihydroquinidine barbiturate, decreases the effect of griseofulvin.
DB00741
Hydrocortisone
The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone.
DB00458
Imipramine
Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, imipramine.
DB01137
Levofloxacin
Increased risk of cardiotoxicity and arrhythmias
DB00367
Levonorgestrel
Phenobarbital decreases the effect of levonorgestrel
DB01378
Magnesium
The antiacid decreases the absorption of quinidine
DB00333
Methadone
The barbiturate, dihydroquinidine barbiturate, decreases the effect of methadone.
DB00916
Metronidazole
The barbiturate, dihydroquinidine barbiturate, decreases the effect of metronidazole.
DB00218
Moxifloxacin
Increased risk of cardiotoxicity and arrhythmias
DB00220
Nelfinavir
Nelfinavir increases the effect and toxicity of quindine
DB01115
Nifedipine
Decreased quinidine effect, increased nifedipine effect
DB00540
Nortriptyline
Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline.
DB01165
Ofloxacin
Increased risk of cardiotoxicity and arrhythmias
DB01303
Oxtriphylline
The barbiturate, dihydroquinidine barbiturate, decreases the effect of oxtriphylline.
DB00860
Prednisolone
The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone.
DB00635
Prednisone
The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisone.
DB01035
Procainamide
Quinidine increases the effect of procainamide
DB01182
Propafenone
Quinidine increases the effect of propafenone
DB00908
Quinidine
The anticonvulsant, dihydroquinidine. barbiturate, decreases the effect of quinidine.
DB01369
Quinupristin
This combination presents an increased risk of toxicity
DB00277
Theophylline
The barbiturate, dihydroquinidine barbiturate, decreases the effect of theophylline.
DB00620
Triamcinolone
The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone.
BE0000795
Gamma-aminobutyric acid receptor subunit alpha-1
Human
potentiator
# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
yes
Gamma-aminobutyric acid receptor subunit alpha-1
Involved in GABA-A receptor activity
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel
GABRA1
5q34-q35
Membrane; multi-pass membrane protein
252-273
279-300
313-334
422-443
9.61
51802.0
Human
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4075
GenAtlas
GABRA1
GeneCards
GABRA1
GenBank Gene Database
X13584
GenBank Protein Database
31631
IUPHAR
404
Guide to Pharmacology
72
UniProtKB
P14867
UniProt Accession
GBRA1_HUMAN
Gamma-aminobutyric-acid receptor subunit alpha-1 precursor
>Gamma-aminobutyric-acid receptor subunit alpha-1 precursor
MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPG
LGERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASK
IWTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHAC
PLKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVM
TTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA
RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVVPEKPKKVKDP
LIKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKID
RLSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ
>1371 bp
ATGAGGAAAAGTCCAGGTCTGTCTGACTGTCTTTGGGCCTGGATCCTCCTTCTGAGCACA
CTGACTGGAAGAAGCTATGGACAGCCGTCATTACAAGATGAACTTAAAGACAATACCACT
GTCTTCACCAGGATTTTGGACAGACTCCTAGATGGTTATGACAATCGCCTGAGACCAGGA
TTGGGAGAGCGTGTAACCGAAGTGAAGACTGATATCTTCGTCACCAGTTTCGGACCCGTT
TCAGACCATGATATGGAATATACAATAGATGTATTTTTCCGTCAAAGCTGGAAGGATGAA
AGGTTAAAATTTAAAGGACCTATGACAGTCCTCCGGTTAAATAACCTAATGGCAAGTAAA
ATCTGGACTCCGGACACATTTTTCCACAATGGAAAGAAGTCAGTGGCCCACAACATGACC
ATGCCCAACAAACTCCTGCGGATCACAGAGGATGGCACCTTGCTGTACACCATGAGGCTG
ACAGTGAGAGCTGAATGTCCGATGCATTTGGAGGACTTCCCTATGGATGCCCATGCTTGC
CCACTAAAATTTGGAAGTTATGCTTATACAAGAGCAGAAGTTGTTTATGAATGGACCAGA
GAGCCAGCACGCTCAGTGGTTGTAGCAGAAGATGGATCACGTCTAAACCAGTATGACCTT
CTTGGACAAACAGTAGACTCTGGAATTGTCCAGTCAAGTACAGGAGAATATGTTGTTATG
ACCACTCATTTCCACTTGAAGAGAAAGATTGGCTACTTTGTTATTCAAACATACCTGCCA
TGCATAATGACAGTGATTCTCTCACAAGTCTCCTTCTGGCTCAACAGAGAGTCTGTACCA
GCAAGAACTGTCTTTGGAGTAACAACTGTGCTCACCATGACAACATTGAGCATCAGTGCC
AGAAACTCCCTCCCTAAGGTGGCTTATGCAACAGCTATGGATTGGTTTATTGCCGTGTGC
TATGCCTTTGTGTTCTCAGCTCTGATTGAGTTTGCCACAGTAAACTATTTCACTAAGAGA
GGTTATGCATGGGATGGCAAAAGTGTGGTTCCAGAAAAGCCAAAGAAAGTAAAGGATCCT
CTTATTAAGAAAAACAACACTTACGCTCCAACAGCAACCAGCTACACCCCTAATTTGGCC
AGGGGCGACCCGGGCTTAGCCACCATTGCTAAAAGTGCAACCATAGAACCTAAAGAGGTC
AAGCCCGAAACAAAACCACCAGAACCCAAGAAAACCTTTAACAGTGTCAGCAAAATTGAC
CGACTGTCAAGAATAGCCTTCCCGCTGCTATTTGGAATCTTTAACTTAGTCTACTGGGCT
ACGTATTTAAACAGAGAGCCTCAGCTAAAAGCCCCCACACCACATCAATAG
PF02931
Neur_chan_LBD
PF02932
Neur_chan_memb
component
intrinsic to membrane
component
integral to membrane
component
membrane
component
postsynaptic membrane
component
cell
function
GABA receptor activity
function
ion transporter activity
function
GABA-A receptor activity
function
ion channel activity
function
signal transducer activity
function
ligand-gated ion channel activity
function
receptor activity
function
extracellular ligand-gated ion channel activity
function
transporter activity
function
transmembrane receptor activity
function
neurotransmitter receptor activity
process
signal transduction
process
cell surface receptor linked signal transduction
process
gamma-aminobutyric acid signaling pathway
process
ion transport
process
G-protein coupled receptor protein signaling pathway
process
anion transport
process
inorganic anion transport
process
chloride transport
process
physiological process
process
cellular physiological process
process
transport
process
cellular process
process
cell communication
"
|
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| owl:sameAs | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| owl:sameAs | |
| owl:sameAs | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| drugbank:interactsWith | |
| owl:sameAs | |
| owl:sameAs |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines3/drugbank_small.nt
The resource appears as object in 94 triples